Aly M, Shahhat S, Nguyen T
Cureus. 2024; 16(8):e67835.
PMID: 39323699
PMC: 11424013.
DOI: 10.7759/cureus.67835.
Niitsu H, Mizumoto M, Li Y, Nakamura M, Ishida T, Iizumi T
Cancers (Basel). 2024; 16(2).
PMID: 38254846
PMC: 10814092.
DOI: 10.3390/cancers16020357.
Mheid S, Allen S, Ng S, Hall W, Sanford N, Aguilera T
Curr Oncol. 2023; 30(10):9230-9243.
PMID: 37887567
PMC: 10605011.
DOI: 10.3390/curroncol30100667.
Omiya Y, Morisaka H, Matsuda M, Saito M, Hashimoto T, Motosugi U
Abdom Radiol (NY). 2023; 48(11):3353-3361.
PMID: 37542553
DOI: 10.1007/s00261-023-03995-x.
Mai Z, Yang Q, Xu J, Xie H, Ban X, Xu G
Abdom Radiol (NY). 2023; 48(6):1995-2007.
PMID: 36939911
PMC: 10167191.
DOI: 10.1007/s00261-023-03827-y.
Early complete tumor response as a survival predictor in hepatocellular carcinoma patients receiving stereotactic body radiation therapy.
Wu Q, Chen Y, Du S, Hu Y, Yang P, Zeng Z
Clin Transl Radiat Oncol. 2023; 39:100465.
PMID: 36935858
PMC: 10014333.
DOI: 10.1016/j.ctro.2022.03.010.
Liver magnetic resonance imaging for evaluation of response to treatment after stereotactic body radiation therapy of hepatocellular carcinoma.
Serafini A, Ruggeri V, Inchingolo R, Gatti M, Guarneri A, Maino C
World J Hepatol. 2022; 14(9):1790-1803.
PMID: 36185716
PMC: 9521449.
DOI: 10.4254/wjh.v14.i9.1790.
Paclitaxel-loaded PLGA microspheres with a novel morphology to facilitate drug delivery and antitumor efficiency.
Zhang Z, Wang X, Li B, Hou Y, Cai Z, Yang J
RSC Adv. 2022; 8(6):3274-3285.
PMID: 35541195
PMC: 9077493.
DOI: 10.1039/c7ra12683b.
Radiomics-Based Predictive Model of Radiation-Induced Liver Disease in Hepatocellular Carcinoma Patients Receiving Stereo-Tactic Body Radiotherapy.
Shen P, Huang W, Dai Y, Lo C, Yang J, Su Y
Biomedicines. 2022; 10(3).
PMID: 35327398
PMC: 8945465.
DOI: 10.3390/biomedicines10030597.
Locoregional Liver-Directed Therapies to Treat Unresectable Colorectal Liver Metastases: A Review.
McFadden N, Perry L, Ghalambor T, Langan R, Gholami S
Oncology (Williston Park). 2022; 36(2):108-114.
PMID: 35180338
PMC: 10030047.
DOI: 10.46883.2022.25920945.
Commentary: Stereotactic Body Radiotherapy vs. Radiofrequency Ablation in the Treatment of Hepatocellular Carcinoma: A Meta-Analysis.
Li Z, Jiao D, Han X
Front Oncol. 2021; 11:633417.
PMID: 34084741
PMC: 8168374.
DOI: 10.3389/fonc.2021.633417.
Gallbladder cancer revisited: the evolving role of a radiologist.
Ramachandran A, Srivastava D, Madhusudhan K
Br J Radiol. 2020; 94(1117):20200726.
PMID: 33090880
PMC: 7774702.
DOI: 10.1259/bjr.20200726.
Retrospective assessment of a single fiducial marker tracking regimen with robotic stereotactic body radiation therapy for liver tumours.
Nakayama M, Uehara K, Nishimura H, Tamura S, Munetomo Y, Tsudou S
Rep Pract Oncol Radiother. 2019; 24(4):383-391.
PMID: 31297039
PMC: 6595081.
DOI: 10.1016/j.rpor.2019.06.001.
Evaluation of Hepatic Toxicity after Repeated Stereotactic Body Radiation Therapy for Recurrent Hepatocellular Carcinoma using Deformable Image Registration.
Lee S, Kim H, Ji Y, Cho B, Kim S, Jung J
Sci Rep. 2018; 8(1):16224.
PMID: 30385839
PMC: 6212421.
DOI: 10.1038/s41598-018-34676-1.
Magnetic Resonance Imaging Evaluation of Hepatocellular Carcinoma Treated With Stereotactic Body Radiation Therapy: Long Term Imaging Follow-Up.
Mendiratta-Lala M, Masch W, Shankar P, Hartman H, Davenport M, Schipper M
Int J Radiat Oncol Biol Phys. 2018; 103(1):169-179.
PMID: 30213751
PMC: 6301102.
DOI: 10.1016/j.ijrobp.2018.09.004.
Direct dose correlation of MRI morphologic alterations of healthy liver tissue after robotic liver SBRT.
Boda-Heggemann J, Jahnke A, Chan M, Ghaderi Ardekani L, Hunold P, Schafer J
Strahlenther Onkol. 2018; 194(5):414-424.
PMID: 29404626
DOI: 10.1007/s00066-018-1271-9.
Imaging Findings Within the First 12 Months of Hepatocellular Carcinoma Treated With Stereotactic Body Radiation Therapy.
Mendiratta-Lala M, Gu E, Owen D, Cuneo K, Bazzi L, Lawrence T
Int J Radiat Oncol Biol Phys. 2017; 102(4):1063-1069.
PMID: 29029891
PMC: 5826807.
DOI: 10.1016/j.ijrobp.2017.08.022.